Arch Biopartners Inc. (ARCH.V)
CAD 1.73
(-0.57%)
CAD 1.73
(-0.57%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.35 Million CAD | -141.49% |
| 2022 | -1.38 Million CAD | -19.27% |
| 2021 | -1.16 Million CAD | 74.86% |
| 2020 | -4.63 Million CAD | -96.19% |
| 2019 | -2.36 Million CAD | 26.92% |
| 2018 | -3.23 Million CAD | -69.96% |
| 2017 | -1.9 Million CAD | -90.05% |
| 2016 | -1 Million CAD | -10.34% |
| 2015 | -906.89 Thousand CAD | -143.12% |
| 2014 | -373.02 Thousand CAD | -95.07% |
| 2013 | -191.22 Thousand CAD | 41.94% |
| 2012 | -329.38 Thousand CAD | 25.6% |
| 2011 | -442.68 Thousand CAD | -213.9% |
| 2010 | -141.02 Thousand CAD | 22.42% |
| 2009 | -181.79 Thousand CAD | 45.77% |
| 2008 | -335.22 Thousand CAD | -43.68% |
| 2007 | -233.31 Thousand CAD | -458.13% |
| 2006 | 65.14 Thousand CAD | 118.52% |
| 2005 | -351.75 Thousand CAD | 66.94% |
| 2004 | -1.06 Million CAD | -94.37% |
| 2003 | -547.37 Thousand CAD | -146.15% |
| 2002 | -222.37 Thousand CAD | -13.75% |
| 2001 | -195.49 Thousand CAD | 80.51% |
| 2000 | -1 Million CAD | -35.78% |
| 1999 | -738.66 Thousand CAD | -43.84% |
| 1998 | -513.53 Thousand CAD | 56.43% |
| 1997 | -1.17 Million CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1 Million CAD | -349.57% |
| 2024 Q3 | -862.93 Thousand CAD | 73.36% |
| 2024 Q2 | -3.23 Million CAD | -223.52% |
| 2023 Q3 | -577.42 Thousand CAD | 40.36% |
| 2023 FY | -5.24 Million CAD | -277.44% |
| 2023 Q4 | 401.25 Thousand CAD | 169.49% |
| 2023 Q2 | -968.23 Thousand CAD | 56.2% |
| 2023 Q1 | -2.21 Million CAD | -384.93% |
| 2022 Q1 | -179.38 Thousand CAD | -126.93% |
| 2022 Q3 | -264.62 Thousand CAD | 45.94% |
| 2022 FY | -1.38 Million CAD | -19.27% |
| 2022 Q4 | -455.89 Thousand CAD | -72.28% |
| 2022 Q2 | -489.46 Thousand CAD | -172.85% |
| 2021 Q2 | -1.05 Million CAD | 36.1% |
| 2021 FY | -1.16 Million CAD | 74.86% |
| 2021 Q4 | 666.23 Thousand CAD | -24.05% |
| 2021 Q3 | 877.24 Thousand CAD | 183.07% |
| 2021 Q1 | -1.65 Million CAD | -2.6% |
| 2020 Q3 | -2.22 Million CAD | -2189.67% |
| 2020 Q1 | -732.6 Thousand CAD | 24.39% |
| 2020 FY | -4.63 Million CAD | -96.19% |
| 2020 Q4 | -1.61 Million CAD | 27.56% |
| 2020 Q2 | -97.1 Thousand CAD | 86.75% |
| 2019 Q4 | -968.93 Thousand CAD | -1112.13% |
| 2019 Q3 | -79.93 Thousand CAD | 84.29% |
| 2019 FY | -2.36 Million CAD | 26.92% |
| 2019 Q2 | -508.66 Thousand CAD | 39.01% |
| 2019 Q1 | -834.02 Thousand CAD | -7.47% |
| 2018 Q2 | -615.3 Thousand CAD | -80.52% |
| 2018 Q1 | -340.84 Thousand CAD | -55.22% |
| 2018 FY | -3.23 Million CAD | -69.96% |
| 2018 Q4 | -776.05 Thousand CAD | 48.26% |
| 2018 Q3 | -1.49 Million CAD | -143.77% |
| 2017 Q4 | -219.58 Thousand CAD | 83.18% |
| 2017 Q3 | -1.3 Million CAD | -752.52% |
| 2017 FY | -1.9 Million CAD | -90.05% |
| 2017 Q1 | -235.36 Thousand CAD | 31.61% |
| 2017 Q2 | -153.13 Thousand CAD | 34.94% |
| 2016 Q3 | -182.42 Thousand CAD | 40.81% |
| 2016 FY | -1 Million CAD | -10.34% |
| 2016 Q1 | -165.88 Thousand CAD | 13.01% |
| 2016 Q2 | -308.19 Thousand CAD | -85.79% |
| 2016 Q4 | -344.14 Thousand CAD | -88.65% |
| 2015 FY | -906.89 Thousand CAD | -143.12% |
| 2015 Q2 | -192.24 Thousand CAD | 47.46% |
| 2015 Q3 | -158.08 Thousand CAD | 17.77% |
| 2015 Q4 | -190.69 Thousand CAD | -20.63% |
| 2015 Q1 | -365.87 Thousand CAD | -253.19% |
| 2014 Q1 | -52.76 Thousand CAD | 13.07% |
| 2014 Q2 | -91.81 Thousand CAD | -74.01% |
| 2014 Q4 | -103.59 Thousand CAD | 17.03% |
| 2014 FY | -373.02 Thousand CAD | -95.07% |
| 2014 Q3 | -124.85 Thousand CAD | -35.99% |
| 2013 Q2 | -80.04 Thousand CAD | -146.1% |
| 2013 Q4 | -60.69 Thousand CAD | -237.8% |
| 2013 Q1 | -32.52 Thousand CAD | 65.48% |
| 2013 Q3 | -17.96 Thousand CAD | 77.55% |
| 2013 FY | -191.22 Thousand CAD | 41.94% |
| 2012 Q2 | -59.97 Thousand CAD | 31.25% |
| 2012 Q4 | -94.21 Thousand CAD | -6.01% |
| 2012 FY | -329.38 Thousand CAD | 25.6% |
| 2012 Q3 | -88.87 Thousand CAD | -48.19% |
| 2012 Q1 | -87.22 Thousand CAD | 2.78% |
| 2011 Q4 | -89.72 Thousand CAD | 45.16% |
| 2011 FY | -442.68 Thousand CAD | -213.9% |
| 2011 Q3 | -163.6 Thousand CAD | -101.88% |
| 2011 Q2 | -81.03 Thousand CAD | 25.19% |
| 2011 Q1 | -108.32 Thousand CAD | -33.86% |
| 2010 Q2 | -24.03 Thousand CAD | 75.61% |
| 2010 FY | -141.02 Thousand CAD | 22.42% |
| 2010 Q4 | -80.92 Thousand CAD | -169.45% |
| 2010 Q3 | -30.03 Thousand CAD | -24.94% |
| 2010 Q1 | -98.57 Thousand CAD | -268.27% |
| 2009 Q4 | -26.76 Thousand CAD | 24.96% |
| 2009 FY | -181.79 Thousand CAD | 45.77% |
| 2009 Q2 | -57.5 Thousand CAD | 76.22% |
| 2009 Q3 | -35.66 Thousand CAD | 37.98% |
| 2009 Q1 | -241.86 Thousand CAD | -372.97% |
| 2008 Q4 | 88.6 Thousand CAD | 223.31% |
| 2008 Q3 | -71.85 Thousand CAD | 34.74% |
| 2008 FY | -335.22 Thousand CAD | -43.68% |
| 2008 Q2 | -110.1 Thousand CAD | 37.85% |
| 2008 Q1 | -177.17 Thousand CAD | -1504.39% |
| 2007 Q2 | -40.53 Thousand CAD | -116.62% |
| 2007 FY | -233.31 Thousand CAD | -458.13% |
| 2007 Q4 | -11.04 Thousand CAD | -141.85% |
| 2007 Q3 | -4566.00 CAD | 88.74% |
| 2007 Q1 | 243.84 Thousand CAD | 593.22% |
| 2006 FY | 65.14 Thousand CAD | 118.52% |
| 2006 Q4 | -49.43 Thousand CAD | -112.2% |
| 2006 Q3 | -23.29 Thousand CAD | 75.47% |
| 2006 Q2 | -94.99 Thousand CAD | 57.77% |
| 2006 Q1 | -224.92 Thousand CAD | -243.16% |
| 2005 Q2 | -167.06 Thousand CAD | 74.69% |
| 2005 Q1 | -660.14 Thousand CAD | -91.87% |
| 2005 FY | -351.75 Thousand CAD | 66.94% |
| 2005 Q4 | 157.11 Thousand CAD | 234.42% |
| 2005 Q3 | -116.88 Thousand CAD | 30.03% |
| 2004 FY | -1.06 Million CAD | -94.37% |
| 2004 Q1 | -358.58 Thousand CAD | -267.67% |
| 2004 Q2 | -103.05 Thousand CAD | 71.26% |
| 2004 Q3 | 45.5 Thousand CAD | 144.15% |
| 2004 Q4 | -344.05 Thousand CAD | -856.17% |
| 2003 Q1 | -50.89 Thousand CAD | -195.45% |
| 2003 FY | -547.37 Thousand CAD | -146.15% |
| 2003 Q4 | -97.53 Thousand CAD | -525.4% |
| 2003 Q3 | -15.59 Thousand CAD | 79.39% |
| 2003 Q2 | -75.66 Thousand CAD | -48.66% |
| 2002 FY | -222.37 Thousand CAD | -13.75% |
| 2002 Q3 | -82.08 Thousand CAD | -19.81% |
| 2002 Q4 | -17.22 Thousand CAD | 79.01% |
| 2002 Q1 | -8874.00 CAD | 90.12% |
| 2002 Q2 | -68.5 Thousand CAD | -672.02% |
| 2001 Q4 | -89.85 Thousand CAD | -60.73% |
| 2001 Q3 | -55.9 Thousand CAD | -36.19% |
| 2001 Q2 | -41.04 Thousand CAD | 89.98% |
| 2001 Q1 | -409.6 Thousand CAD | -75.48% |
| 2001 FY | -195.49 Thousand CAD | 80.51% |
| 2000 Q2 | -59.11 Thousand CAD | 87.08% |
| 2000 FY | -1 Million CAD | -35.78% |
| 2000 Q1 | -457.43 Thousand CAD | -446.01% |
| 2000 Q4 | -233.42 Thousand CAD | 22.4% |
| 2000 Q3 | -300.81 Thousand CAD | -408.9% |
| 1999 Q4 | -83.77 Thousand CAD | 34.7% |
| 1999 FY | -738.66 Thousand CAD | -43.84% |
| 1999 Q1 | -274.85 Thousand CAD | -396.22% |
| 1999 Q2 | -69.15 Thousand CAD | 74.84% |
| 1999 Q3 | -128.29 Thousand CAD | -85.5% |
| 1998 FY | -513.53 Thousand CAD | 56.43% |
| 1998 Q4 | -55.38 Thousand CAD | 56.69% |
| 1998 Q2 | -127.9 Thousand CAD | 0.0% |
| 1998 Q3 | -127.9 Thousand CAD | 0.0% |
| 1997 FY | -1.17 Million CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Covalon Technologies Ltd. | -4.48 Million CAD | 25.26% |
| Hemostemix Inc. | -2.33 Million CAD | -43.78% |
| Universal Ibogaine Inc. | 497.15 Thousand CAD | 774.877% |
| Kane Biotech Inc. | -3.35 Million CAD | 0.066% |
| MedMira Inc. | -1.94 Million CAD | -72.562% |
| Marvel Biosciences Corp. | -2.31 Million CAD | -44.685% |
| NervGen Pharma Corp. | -17.77 Million CAD | 81.126% |
| XORTX Therapeutics Inc. | -6.38 Million CAD | 47.427% |